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1. Introduction  
Cilnidipine is a unique dihydropyridine derivative Ca2+ channel blocker with an inhibitory 
action on the sympathetic N-type Ca2+ channels (Uneyama et al., 1999a). It has been clarified 
that cilnidipine exerts antisympathetic actions in various examinations from cell to human 
levels. Furthermore, its renoprotective, neuroprotective and cardioprotective effects have 
been demonstrated in clinical practice or animal examinations. After the introduction of 
nifedipine, many Ca2+ channel blockers with long-lasting action have been synthesized to 
decline sympathetic reflex during antihypertensive therapy. Based on each pharmacokinetic 
profile, Ca2+ channel blockers have been divided into three groups; namely, 1st, 2nd, and 
3rd generation. Since cilnidipine directly inhibits the sympathetic neurotransmitter release 
by N-type Ca2+ channel-blocking property, the drug can be expected as 4th generation, 
providing an effective strategy for the treatment of cardiovascular diseases (Takahara, 2009).  
Recently, cilnidipine has been demonstrated to suppress renin-angiotensin-aldosterone 
system at anti-hypertensive doses in animal examinations, whereas other Ca2+ channel 
blockers usually activates such vasopressor system after acute or repeated administrations. 
Interestingly, antihypertensive therapies with angiotensin II receptor blockers sometimes 
activate renin-angiotensin system, which is effectively suppressed by cilnidipine. This may 
provide synergistic and effective therapeutic strategies during combined administration of 
cilnidipine and angiotensin II receptor blockers. The possible mechanisms to suppress renin-
angiotensin-aldosterone system appear to be clarified. In human adrenocortical cells, where 
N-type Ca2+ channels are recently found to act as a source of intracellular Ca2+ mobilization, 
cilnidipine as well as a specific N-type Ca2+ channel blocker ω-conotoxin effectively inhibits 
angiotensin II-induced aldosterone synthesis. 
In this chapter, we introduce a pharmacological profile of cilnidipine in combined with its 
clinical antihypertensive and anti-sympathetic actions. We further review utilities of 
cilnidipine for management of hypertension and its complications through inhibition of 
sympathetic N-type Ca2+ channels and renin-angiotensin-aldosterone system. 
2. Ca
2+
 channels: Physiological role and pharmacological modification 
Rise in intracellular Ca2+ triggers a variety of physiological processes, and there are many 
channels and pumps involved in controlling intracellular Ca2+ level. Among them, voltage-
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gated Ca2+ channels play a key role in this process, which is a pharmacological target 
molecule for so-called Ca2+ channel blockers. In excitatory cells such as smooth and cardiac 
muscle cells and neurons, high voltage-activated (HVA) Ca2+ channels are well known to 
regulate a variety of cellular events, which include muscle contraction, neuronal electrical 
activity, the release of neurotransmitters and hormones as well as gene expressions. On the 
other hand, low voltage-activated (LVA) Ca2+ channels are expressed throughout the body, 
including nervous tissue, heart, kidney, smooth muscle and many endocrine organs. The 
channels in the brain are considered to be involved in repetitive low threshold firing and 
nociception. In the heart, they are expressed in the sino-atrial node and are considered to 
participate in cardiac pacemaking (Tanaka & Shigenobu, 2005). 
2.1 Classification of Ca
2+
 channels 
Ca2+ channels are classified into at least 6 subtypes; namely, L-, N-, P-, Q-, R-, and T-type, 
based on electrophysiological and pharmacological evidences (Varadi et al., 1995). The T-
type Ca2+ channels are known as low-voltage-activated Ca2+ channels that activate and 
deactivate slowly, but inactivate rapidly. The other five types of Ca2+ channels are all high-
voltage-activated Ca2+ channels, which depolarize at approximately –40 mV. Molecular 
biological techniques have shown that Ca2+ channels are composed of ┙1, ┙2-├, ┚, and ┛ 
subunits using L-type Ca2+ channels from skeletal muscles. In particular, the ┙l subunit 
forms the Ca2+ transmission pore, which fulfills the most important function. Furthermore, 
10 ┙1 subunits have been cloned and classified into 3 subfamilies: Cav1.x; Cav2.x; and 
Cav3.x, based on their gene sequence similarity (Catterall et al., 2003). More importantly, the 
┙1 subunit has a binding site for Ca2+ channel blockers.  
2.2 Ca
2+
 channels in the cardiovascular system 
In the cardiovascular system, L-type Ca2+ channels are predominantly expressed in the heart 
and vessels, which regulate cardiac contractility, sinus nodal function and vascular tone. ┚-
adrenergic stimulation enhances the force of cardiac contraction through activation of cAMP-
mediated activation of protein kinase A that in turn increases the L-type Ca2+ channel currents, 
causing a greater rate of release of Ca2+ from the sarcoplasmic reticulum. In the arterial vessels, 
receptor stimulation or membrane depolarization activates Ca2+ influx through Ca2+ channels 
and myosin light chain kinase, leading to smooth muscle contraction. Thus, L-type Ca2+ 
channels have been recognized as a pharmacological target for the treatment of cardiovascular 
disease. Most of Ca2+ channel blockers are well known to have selectivity for vascular tissues 
rather than cardiac function. On the other hand, verapamil, diltiazem and bepridil have been 
shown to possess less vascular selectivity, which are used for supraventricular and/or 
ventricular arrhythmias. The selectivity of Ca2+ channel blockers for cardiac and vascular 
actions may be associated with that the membrane potential in vascular smooth muscle cells is 
definitely less negative than the diastolic membrane potential of working cardiac muscle cells. 
In the vascular system, arterioles appear to be more sensitive to Ca2+ channel blockers than 
venules; orthostatic hypotension is not a common adverse effect.  
2.3 Ca
2+
 channels in the sympathetic nerve system 
The most thoroughly characterized role of Ca2+ in the nerve is the triggering of exocytosis. 
The synaptic vesicle cycles at nerve endings could be divided into the following processes: 
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a) translocation of the synaptic vesicle filled with norepinephrine and epinephrine to the 
active zone; b) docking at the active zone and priming; c) fusion triggered by Ca2+ and 
exocytosis; d) endocytosis of empty synaptic vesicle to become coated vesicles; e) endosome 
fusion and budding to make the synaptic vesicle re-generation; and f) the neurotransmitters 
uptake to the regenerated synaptic vesicle. Entered Ca2+ through voltage-gated Ca2+ 
channels bind to synaplotagmin, changing the conformation of a large protein superfamily 
called as SNARE complexes (formed by 4 ┙-helices; synaptobrevin, synaptotagmin, syntaxin 
and SNAP 25), leading to fusion of vesicle membrane into plasma membrane. At these steps, 
the N-type Ca2+ channel plays an important role as a Ca2+ supplier. More than 60 Ca2+ 
channels open for each vesicle for rapid release (Uneyama et al., 1999). 
In the sympathetic nervous systems, N-type Ca2+ channels are localized at the nerve 
endings. Using a patch clamp method, N-type Ca2+ channels are shown to contribute about 
85% of all other types of Ca2+ channels in the sympathetic neuronal cells. N-type Ca2+ 
channels have been demonstrated to predominantly regulate norepinephrine release in the 
superior cervical ganglia neurons using a selective N-type Ca2+ channel blocker ω-conotoxin 
GVIA (Hirning et al., 1988). This finding was further supported by subsequent experiments 
using isolated rat arterial preparations. In a clinical study, systemic administration of ω-
conotoxin MVIIA (SNX-111) has been shown to induce sympatholytic action. 
2.4 Ca
2+
 channels in the adrenal gland 
Chromaffin cells in the medulla of the adrenal gland are innervated by the splanchnic nerve 
and secrete catecholamines into the blood stream. In anesthetized dogs, the splanchnic nerve 
stimulation increased the catecholamine secretion from adrenal gland, which was effectively 
inhibited by an N-type Ca2+ channel blocker ω-conotoxin GVIA but not by L-type Ca2+ 
channel blockers nifedipine or verapamil (Kimura et al., 1994). Many in vitro studies also 
support that N-type Ca2+ channels are localized at chromaffin cells to regulate the release of 
catecholamine. Recently, it is shown that N-type Ca2+ channels are also localized at the 
human adrenocortical cells, playing an important role in the secretion of adrenocortical 
hormones (Aritomi et al., 2011a). Furthermore, N-type Ca2+ channels may offer the different 
way of controlling corticosteroid production in adrenocortical cells than other types of 
voltage-gated Ca2+ channels. 
3. New generation Ca
2+ 
channel blocker: Cilnidipine 
Cilnidipine is a unique dihydropyridine derivative L-type Ca2+ channel blocker with an 
inhibitory action on the sympathetic N-type Ca2+ channels. As shown in Fig. 1, Ca2+ channels 
are ordinarily activated by membrane depolarization in the vascular cells or sympathetic 
neurons, leading to vascular contraction or neurotransmitter releases. During 
antihypertensive therapies with pure L-type Ca2+ channel blockers like nifedipine, the 
sympathetic reflex is sometimes occurred due to hypotension, leading to activation of 
sympathetic N-type Ca2+ channels, which induces several cardiovascular responses 
including vascular contraction, tachycardia and renin secretion (Takahara 2009). Cilnidipine 
can directly inhibit the sympathetic neurotransmitter release by its N-type Ca2+ channel-
blocking property, which may reduce risk of cardiovascular diseases closely associated with 
sympathetic nerve activation. The wide variety of pharmacological actions of cilnidipine has 
been investigated, which is summarized in Table 1. 
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Fig. 1. Diagrammatic representation of L/N-type dual action of cilnidipine. Cilnidipine 
directly inhibits the sympathetic neurotransmitter (norepinephrine; NE) release by N-type 
Ca2+ channel-blocking property in addition to vascular L-type Ca2+ channel inhibition, 
leading to suppression of renin-angiotensin-aldosterone system (RAAS). Thus, the drug can 
be expected to provide an effective strategy for the treatment of cardiovascular diseases 
(CVD). 
3.1 Pharmacology 
L-type Ca2+ channel-blocking actions of cilnidipine were widely examined in earlier 
experimental studies, showing that its potency was greater than that of nifedipine. In 1997, 
N-type Ca2+ channel-blocking action was found in cilnidipine (Uneyama et al., 1997). 
Submicromolecular concentrations of cilnidipine effectively suppressed N-type Ca2+ 
channel currents in isolated sympathetic neurons. The inhibitory effect of various 
dihydropyridines on cardiac L-type Ca2+ channels was further compared in isolated 
ventricular myocytes with that on N-type Ca2+ channels in superior cervical ganglion 
neurons of the rat (Uneyama et al., 1999b). In that study, all dihydropyridines, except 
cilnidipine, showed a small inhibitory effect at a concentration of 1 µM. The N-type 
channel-blocking action of cilnidipine has also been confirmed in IMR-32 human 
neuroblastoma cells and PC12 pheochromocytoma of the rat adrenal medulla cells. 
Furthermore, it has been demonstrated that the N-type Ca2+ channel-blocking effects of 
cilnidipine leading to anti-sympathetic action can be observed at its anti-hypertensive 
doses (Takahara et al., 2002). 
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Mode of action Inhibition of L-type Ca2+ channels (vascular smooth muscle, 
in vitro); inhibition of N-type Ca2+ channels (sympathetic 
neuron, in vitro) 
Pharmacology 
 1) Cardiovascular action Vascular relaxation (in vitro); hypotensive action (in vivo) 
 2) Anti-sympathetic action Decrease of catecholamine release, tissue (kidney) 
norepinephrine level, (in vitro, in vivo); inhibition of 
sympathetic tachycardia and cold stress-induced 
vasoconstriction (in vivo); decrease in plasma/urinary 
norepinephrine, muscle sympathetic nerve activity, low 
frequency/high frequency ratio (LF/HF ratio), and plasma 
level of ß-thromboglobulin (clinical) 
3) Suppression of renin- 
angiotensin-aldosterone system 
Decrease in plasma level of angiotensin II and aldosterone  
(in vivo, clinical); inhibition of aldosterone production 
(adrenocortical cells, in vitro); inhibition of reflex aldosterone 
production, and angiotensin II-renin feedback (in vivo) 
 4) Anti-oxidation Inhibition of NADPH oxidase-derived superoxide production 
(kidney, in vivo)  
 5) Others Improvement of insulin resistance (in vivo); increases of nitric 
oxide production (in vitro); protection from retinal neuronal 
injury (in vivo); anti-nociception (in vivo) 
Antihypertensive action 
1) Animal model Antihypertensive action in spontaneously hypertensive rats, 
stroke-prone spontaneously hypertensive rat, renal 
hypertensive rats, DOCA-salt hypertensive rats, Otsuka 
Long-Evans Tokushima Fatty rat, Dahl salt sensitive rat and 
2-kidney 1-clip hypertensive dogs (in vivo) 
2) Human Essential hypertension; severe hypertension; hypertension 
with chronic kidney disease, cerebrovascular disease or 
diabetes (clinical) 
Actions in key organs 
1) Kidney Increase in renal blood flow; dilation of afferent and efferent 
arterioles; natriuresis; inhibition of renal nerve stimulation-
induced antinatriuresis; suppression of albuminuria; 
glomerular hypertrophy and interstitial fibrosis; decrease in 
renal angiotensin II content (in vivo); decrease in albuminuria 
and urinary protein (clinical) 
2) Heart Increase in coronary blood flow (in vitro, in vivo); 
suppression of vasopressin-induced ST depression; reduction 
of the myocardial infarct size and incidence of ventricular 
premature beats after ischemia-reperfusion; abbreviation of 
abnormally prolonged ventricular repolarization (in vivo); 
decrease in BNP, LV mass index, heart rate and 
cardiothoracic ratio (clinical) 
3) Brain Downward shift of the lower limit of autoregulation for 
cerebral blood flow; reduction of the cerebral infarction size 
(in vivo); increase in cerebral blood flow (clinical) 
Table 1. Summary of pharmacological effects of cilnidipine 
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3.2 Antihypertensive action 
In animal examinations, cilnidipine has a slow-onset and long-lasting antihypertensive 
action in spontaneously hypertensive rats, renal hypertensive rats, DOCA-salt hypertensive 
rats, and 2-kidney 1-clip hypertensive dogs. In addition, cilnidipine significantly decreases 
the blood pressure of stroke-prone spontaneously hypertensive rats (Watanabe et al. 1995a) 
and Dahl salt-sensitive rats (Aritomi et al., 2010).   
In clinical studies, the antihypertensive effect of cilnidipine has been demonstrated in 
hypertensive patients, and also in patients with severe hypertension or with complications 
such as chronic kidney disease, cerebrovascular disease and diabetes. Cilnidipine has been 
reported to improve some hypertensive conditions closely associated with sympathetic 
nerve activation such as morning hypertension, nocturnal hypertension, white-coat 
phenomenon, mental stress and cold stress (Yamagishi, 2006). 
3.3 Anti-sympathetic action 
The anti-sympathetic action of cilnidipine has been demonstrated in several experimental 
studies; increases in the heart rate and plasma catecholamine level induced by cold stress, 
hypotension or spinal nerve stimulation of the rat were effectively suppressed by cilnidipine 
but not other Ca2+ channel blockers (Uneyama et al., 1999a). Importantly, the N-type Ca2+ 
channel-blockade hardly affects parasympathetic neurotransmission (Konda et al., 2001). We 
compared effects of 4 Ca2+ channel blockers (nifedipine, amlodipine, azelnidipine and 
cilnidipine) on hypotension-induced sympathetic activation in the halothane-anesthetized 
canine model (Fig. 2, Takahara et al., 2007; Ishizaka et al., 2010). Intravenous infusion of 
nifedipine or amlodipine decreased the mean blood pressure with increments of heart rate 
and cardiac contractility. Azelnidipine also deceased the mean blood pressure with an 
increment of cardiac contractility whereas marked tachycardia was not induced, which is in 
accordance with a previous report showing its direct suppressive effects on sinus nodal 
automaticity. On the other hand, no significant change in the heart rate or cardiac 
contractility was observed after intravenous infusion of cilnidipine. These results strongly 
indicate that cilnidipine is desirable among Ca2+ channel blockers to minimize reflex 
sympathetic nerve activation. 
Similar actions of cilnidipine can be observed in the clinical investigations using a parameter of 
plasma/urinary norepinephrine, 123I-metaiodobenzylguanidine (MIBG), muscle sympathetic 
nerve activity, low frequency/high frequency ratio (LF/HF ratio) or heart rate, each of which 
help us better understand their clinical effects on sympathetic nerve activity (Takahara 2009). 
More importantly, a clinical study of cold pressor test has shown that cilnidipine decreased 
plasma level of ß-thromboglobulin, a marker of platelet activation, which may prevent arterial 
thrombosis formation associated with increased sympathetic tone. 
3.4 Renal action 
There are observations that L-type Ca2+ channel blockers, such as verapamil, nicardipine, 
felodipine and nifedipine, induce renal vasodilation and natriuresis in anesthetized dogs 
and rats. Similarly, cilnidipine increases the renal blood flow and urinary Na+ excretion 
without affecting creatinine clearance in dogs (Takahara et al., 1997). The kidney is densely 
innervated by adrenergic nerve fibers. The renal nerve stimulation releases norepinephrine  
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and induces renal vasoconstriction, anti-natriuresis and renin secretion via activation of 
adrenoceptors in the vascular vessels, renal tubular cells and granular cells of the 
juxtaglomerular apparatus, respectively, which cannot be suppressed by typical L-type Ca2+ 
channel blockers in several experimental studies (Ogasawara et al., 1993). On the other 
hand, it has been demonstrated that these responses to renal nerve stimulation are 
suppressed by natriuretic doses of cilnidipine via its N-type Ca2+ channel blocking property.  
 
Fig. 2. Comparison of effects of Ca2+ channel blockers on hypotension-induced sympathetic 
activation. Nifedipine, amlodipine, azelnidipine or cilnidipine was intravenously 
administered to halothane-anesthetized dogs, and changes in mean blood pressure, heart 
rate and cardiac contractility were observed. The intravenous doses of nifedipine, 
amlodipine, azelnidipine and cilnidipine used were 3, 200, 70 and 3 µg/kg, respectively. 
Values are expressed as means±SE. Data are quoted and modified from Takahara et al., 2007 
and Ishizaka et al., 2010. 
Glomerular filtration is essentially regulated by afferent and efferent arterial tone. Since 
sensitivity of Ca2+ channel blockers to afferent and efferent arteries varies, Ca2+ channel 
blockers should be appropriately selected for hypertensive patients with chronic kidney 
disease. Since the sympathetic nerves are distributed to the afferent and efferent arteries, N-
www.intechopen.com
 
Antihypertensive Drugs 
 
36
type Ca2+ channel-blocking activity may be partly associated with control of the glomerular 
pressure. Indeed, cilnidipine has been demonstrated to dilate both afferent and efferent 
arteries using the hydronephrotic kidney model of the rat (Konno & Kimura, 2008). 
Furthermore, in renal injury animal models, cilnidipine reduces glomerular capillary 
pressure, afferent and efferent arteriolar resistances, urinary albumin excretion, and 
glomerular volume as well as plasma norepinephrine levels. 
In clinical studies, cilnidipine significantly decreased urinary albumin excretion without 
affecting serum creatinine concentration in hypertensive patients, which is comparable to 
the angiotensin-converting enzyme inhibitor benazepril. Other studies have shown that the 
renal protective effect of cilnidipine was greater than that of pure L-type Ca2+ channel 
blockers. Furthermore, the combination of cilnidipine and valsartan was shown to decrease 
the albumin/creatinine ratio more markedly than valsartan alone. Recently, the multi-center, 
open-labeled and randomized trial of Cilnidipine versus Amlodipine Randomized Trial for 
Evaluation in Renal disease (CARTER) has shown that cilnidipine is superior to amlodipine in 
preventing the progression of proteinuria in patients with hypertension and chronic renal 
disease when coupled with a renin–angiotensin system inhibitor (Fujita et al., 2007).  
3.5 Cardiovascular action 
Since the first generation of Ca2+ channel blockers were known to suppress cardiac functions 
such as contractility, sino-atrial automaticity, and atrioventricular conduction at vasodilator 
doses, pharmaceutical companies have developed new Ca2+ channel blockers with higher 
vascular selectivity in addition to slow kinetics as a new generation. The blood-perfused 
canine heart preparation is an excellent model to quantitatively determine cardio-vascular 
selectivity of Ca2+ channel blockers, and many Ca2+ channel blockers were analyzed using 
this model (Taira, 1987). Cilnidipine has about 10 times more potent coronary vasodilator 
action and higher vascular selectivity than nifedipine in this heart preparation. An in vivo 
experimental study has confirmed that cilnidipine shows anti-anginal effects in the 
vasopressin-induced angina model (Saitoh et al., 2003). A recent study indicates that 
cilnidipine relaxes human arteries through Ca2+ channel antagonism and increases 
production of nitric oxide by enhancement of endothelial nitric oxide synthase in the human 
internal thoracic artery (Fan et al., 2011). 
The cardioprotective action of cilnidipine against ischemia has been analyzed in a rabbit 
model of myocardial infarction, in which cilnidipine decreased the myocardial interstitial 
norepinephrine levels during ischemia and reperfusion periods, leading to reduction of the 
myocardial infarct size and incidence of ventricular premature beats (Nagai et al., 2005). 
Clinically, cilnidipine has been reported to improve left ventricular diastolic function in 
patients with hypertensive heart disease (Kosaka et al., 2009). These cardioprotective actions 
are probably associated with suppression of cardiac sympathetic overactivity via blockade 
of N-type Ca2+ channels and/or anti-oxidative (as described below) effects of cilnidipine, 
which should be further clarified. 
3.6 Cerebrovascular action 
The brain is known to have an autoregulatory capacity that allows cerebral blood vessels to 
maintain constant cerebral blood flow by dilating or contracting in response to abrupt 
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changes in blood pressure. It is demonstrated that the cerebral blood flow was maintained 
regardless of whether blood pressure was decreased by cilnidipine. Furthermore, cilnidipine 
had the activity to shift downward the lower limit of autoregulation for cerebral blood flow 
according to the results of the estimation of the lower limit of autoregulation for cerebral 
blood flow by exsanguination (Watanabe et al., 1995b). Interestingly, an antihypertensive 
and anti-sympathetic dose of cilnidipine reduced the size of cerebral infarction in the rat 
focal brain ischemia model in contrast to nilvadipine (Takahara et al., 2004), which is in 
accordance with previous study using a peptidic N-type Ca2+ channel blocker ω-conotoxin 
MVIIA. Thus, the results may support that N-type Ca2+ channel activation includes 
pathophysiological process of brain ischemia.  
3.7 Metabolic syndrome 
Pancreatic insulin secretion from ┚-cells and glucagon secretion from ┙-cells in the islets of 
Langerhans are Ca2+-dependent processes initiated by Ca2+ influx probably through N-type 
Ca2+ channels. In a study using N-type Ca2+ channel ┙1B-subunit-deficient homozygous 
knockout mice fed normal diet, there was improved glucose tolerance without any change 
in insulin sensitivity, and also body weight gain reduced in the mice fed a high-fat diet 
(Takahashi et al., 2005). In another study with fructose-fed rats, insulin sensitivity was 
significantly lower than in controls, and insulin resistance improved significantly after 
cilnidipine treatment (Takada et al., 2001). These imply that N-type Ca2+ channels play a 
significant role in glucose homeostasis. 
Clinically, it was revealed that cilnidipine significantly reduced 24-hour urinary 
catecholamines in hypertensive patients with type 2 diabetes, and thereby may improve 
insulin resistance (Takeda et al., 1999). Also, it is demonstrated that with cilnidipine 
treatment in patients with obesity, fasting serum immunoreactive insulin (F-IRI) and insulin 
resistance index as assessed by homeostasis model assessment (HOMA-R) lowered, and 
serum dehydroepiandrosterone (DHEA) and serum DHEA-sulfate (DHEA-S) increased 
(Ueshiba & Miyachi, 2002). 
4. Pleiotropic effects of cilnidipine 
Renoprotective, neuroprotective and cardioprotective effects of cilnidipine have been 
demonstrated in clinical practice or animal examinations. It is noticed that cilnidipine may 
have pleiotropic effects besides N-type Ca2+ channel-blocking action. 
4.1 Anti-oxidation 
Dihydropiridine derivatives including nifedipine have been reported to act as lipophilic 
chain-breaking antioxidants; however, there are larger differences in their lipophilicity 
among dihydropyridines. Lipophilicity of cilnidipine is greater than that of amlodipine, 
which implies that cilnidipine itself can reduce oxidative stress independently in addition to 
its N-type Ca2+ channel blockade action.  
Excess reactive oxygen species play an essential role in the development of a variety of renal 
diseases such as glomerulonephritis and tubulointerstitial nephritis. Indeed, in the kidney, 
cilnidipine significantly inhibited the increase in NADPH oxidase-derived superoxide 
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production, whereas amlodipine had no effect on the activation of NADPH oxidase in the 
deoxycorticosterone acetate-salt rat (Toba et al., 2011). Also, cilnidipine elicits podocyte-
protection and anti-proteinuric effect in SHR/ND mcr-cp rat model of spontaneous 
hypertension through the reduction of renal AngII level and a subsequent reduction in 
oxidative stress (Fan et al., 2010). N-type Ca2+ channels localized in podocyte have been 
shown to play an important role in angiotensin II-induced superoxide production, which 
may partly explain the renoprotective mechanisms of cilnidipine. Antiproteinuric effect of 
cilnidipine in the CARTER study (Fujita et al., 2007) is in part explained by its superior 
antioxidant activity.  
In addition, cilnidipine shows neuroprotection in the model of oxidative stress-induced 
neurotoxicity using PC12 cells (Lee et al., 2009), which may partly explain the mechanisms 
of cilnidipine that reduced infarction volume in the rat focal brain ischemia model. 
4.2 Suppression of renin-angiotensin-aldosterone system 
It is widely known that renin secretion from the juxtaglomerular apparatus is closely 
associated with renal sympathetic nerve activity. Thus, cilnidipine may alter renin-
angiotensin-aldosterone system. In recent studies using spontaneously hypertensive rats, 
whereas an L-type Ca2+ channel blocker amlodipine increased plasma renin activity and 
angiotensin II levels at antihypertensive doses, cilnidipine failed to affect plasma renin 
activity or plasma norepinephrine and angiotensin II levels, which strongly supports that 
cilnidipine suppresses renin-angiotensin system through sympathetic N-type Ca2+ channel 
blockade (Konda et al., 2009). In a previous study using the canine cardiac sudden death 
model, it was found for the first time that cilnidipine decreased the plasma concentration 
aldosterone level (Takahara et al., 2009). The curious action of cilnidipine was also 
confirmed in hypertensive rats. A recent study has clearly demonstrated that the endocrine 
mechanisms of angiotensin II-induced aldosterone production in the adrenocortical cells are 
closely associated with activities of N-type Ca2+ channels (Aritomi et al., 2011a). 
Antihypertensive therapies with angiotensin II receptor blockers sometimes activate renin-
angiotensin system. As shown in Fig. 3, increases in plasma renin activity and plasma 
angiotensin II levels can be observed by oral administration of valsartan in spontaneously 
hypertensive rats, which were effectively suppressed by cilnidipine but not by amlodipine 
(Aritomi et al., 2011b). Thus, cilnidipine is expected to provide synergistic and effective 
therapeutic strategies when administered with angiotensin II receptor blockers. 
4.3 Abbreviation of prolonged QT-interval 
The heart of canine chronic atrioventricular block model (cardiac sudden death model) is 
known to have a ventricular electrical remodeling, which mimics the pathophysiology of 
long QT syndrome (Sugiyama, 2008). Using this model, we explored a new pharmacological 
therapeutic strategy for prevention of cardiac sudden death (Fig. 4; Takahara et al., 2009). 
Amlodipine, cilnidipine or an angiotensin II receptor blocker candesartan was orally 
administered to the dogs for 4 weeks. Amlodipine and cilnidipine decreased the blood 
pressure, while candesartan hardly affected it. The QT interval and monophasic action 
potential duration were shortened only in the cilnidipine group, but such effects were not 
observed in the amlodipine or candesartan group. Plasma concentrations of angiotensin II  
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Fig. 3. Effects of combined administration of valsartan and amlodipine or cilnidipine on 
plasma renin activity (A) and plasma angiotensin II (Ang II) level (B) in spontaneously 
hypertensive rats. The oral doses of valsartan, amlodipine and cilnidipine were 10, 1 and 1 
mg/kg, respectively. Values are expressed as means±SE. ##P < 0.01, vehicle vs. valsartan 
alone, *P < 0.05, Ca2+ channel blockers plus valsartan vs. valsartan alone. Data are quoted 
and modified from Aritomi et al., 2011b. 
and aldosterone decreased in the cilnidipine group. On the other hand, elevation of plasma 
concentrations of angiotensin II and aldosterone was detected in the amlodipine group. 
Cilnidipine is expected to restore similar electrical remodeling process to pathophysiology 
of chronic atrioventricular block. Indeed, a recent electrophysiological study has 
demonstrated that some cardiac K+ channels (IKs and Ito) are downregulated in the diabetic 
canine heart, leading to QT interval prolongation. Long QT interval has also been reported 
in patients with various cardiovascular diseases including hypertension with hypertrophy, 
hypertrophic cardiomyopathy and end-stage renal failure (Takahara et al., 2009). Therefore, 
long-term blockade of L/N-type Ca2+ channels may ameliorate the ventricular electrical 
remodeling in the hypertrophied heart leading to QT-interval prolongation, which will 
provide a novel therapeutic strategy. 
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Fig. 4. Effects on electrocardiogram (ECG) and monophasic action potential (MAP) signal 
during idioventricular rhythm in chronic atrioventricular block dogs. A: Typical tracings of 
effects of cilnidipine on ECG and MAP signal. B: Effects of amlodipine (2.5mg/day), 
cilnidipine (5mg/day) and candesartan (12mg/day) on QT interval, MAP duration and 
plasma levels of norepinephrine (NE), angiotensin II (ANG II) and aldosterone (ALDO). 
These parameters were obtained at pre-drug control (C) and 2 weeks (2W) and 4 weeks (4W) 
after the start of drug daily administration. Data are presented as the means±SE. Closed 
symbols represent the significant differences from each pre-drug control (C) value by 
p<0.05.  Data are quoted and modified from Takahara et al., 2009. 
5. Conclusion 
Cilnidipine is a promising Ca2+ channel blocker as the 4th generation with a rational 
pharmacological profile; i.e. dual L/N-type Ca2+ channel-blocking action. The blockade of 
N-type Ca2+ channels effectively suppresses neurohumoral regulation in the cardiovascular 
system, including sympathetic nervous system and renin-angiotensin-aldosterone system. 
Thus, cilnidipine is expected to be favorable for various types of complication of 
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hypertension. Indeed, its advantage is demonstrated by the clinical study showing that 
cilnidipine is superior to amlodipine in preventing the progression of proteinuria in patients 
with hypertension and chronic renal disease (Fujita et al., 2007). The currently described 
information suggests that cilnidipine is a new type of antihypertensive drug distinguished 
from other L-type Ca2+ channel blockers or even other antihypertensives, which will be 
useful for selection of antihypertensive drugs according to the pathophysiological condition 
of a patient. 
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